Dyne Therapeutics, Inc.
DYN$3.00B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM240 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
9wMarket Overview
Stock performance and key metrics
DYN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
zeleciment basivarsen (DYNE-101)
Myotonic Dystrophy Type 1 (DM1)
DYNE-101
Myotonic Dystrophy Type 1 (DM1)
DYNE-251
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
zeleciment basivarsen (DYNE-101) | Phase 3 | Myotonic Dystrophy Type 1 (DM1) | - | - |
DYNE-101 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) | - | - |
DYNE-251 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply